About BiBB

BiBB was founded in 2013 and operates in the global multi-billion dollar market for biopsy accessories. The company is based in Medicon Village in Lund, and was founded by board member Dr. Charles Walther, a cancer researcher at Lund University and a senior physician at the Clinical Pathology Department of Skåne University Hospital in Lund. BiBB develops biopsy instruments under the brand EndoDrill®, enabling earlier and more accurate cancer diagnosis compared to conventional biopsy instruments.

A biopsy involves collecting a sample of tissue where cancer is suspected. Regardless of where the potentially cancerous change is located, a tissue sample is needed to reliably determine whether it is cancer or not. Moreover, if cancer is detected the biopsies need to provide information used to decide treatment and prognosis. The samples are collected using different instruments depending on the organ and what examination method is being used in the individual case. The biopsies are used for microscopic examination and genetic mapping, i.e. information used for optimal “individualised” treatment.

Insufficient or non-representative samples from cancer suspicious lesions delay both information to the patient, if cancer is present or not, and, when relevant, the time to treatment. BiBB is working to improve instruments and methods to meet the growing need of high-quality biopsies that enable faster diagnoses and that can be used to determine treatment and prognosis without repeated sampling sessions.

BiBB develops biopsy instruments for both flexible endoscopy and core needle sampling. Flexible endoscopes are tube-like camera instruments that are inserted into the body’s natural openings to examine organs, such as the stomach, intestines and lungs, then simultaneously collecting samples of tumour suspicious lesions. Needle biopsies are straight, rigid instruments used for basically all types of tumours that can be accessed without endoscopes (e.g. in the breast, prostate or liver). The sampling is usually carried out using imaging techniques like ultrasound and X-ray. Traditional core needle instruments can be difficult to use, collect too little tumour material, or are risky to use due to their spring-loaded sampling mechanism (e.g. close to a blood vessel). However, sampling is crucial to determine whether a lesion is cancer or not. Moreover, the samples must be both large enough and of sufficient quality to provide information needed to decide “personalized” treatment and prognosis.

Millions of biopsies are performed annually to diagnose the most common forms of cancer, and this need is expected to grow as cancer rates are increasing (largely due to the fact that people live longer) and the requirements for early diagnosis are growing. Also, biopsies can be performed via minimally invasive and relatively gentle methods. Consequently, there is a clinical need for new biopsy instruments for earlier and more informative diagnosis.

“As the methods for treating cancer develop, increasing demands are being placed on diagnostics in today’s healthcare. To meet this development, there is an increased need for high quality tumour samples that not only delivers a reliable diagnosis, but also provides information needed for deciding treatment and prognosis. Our EndoDrill® product family is being developed for optimised tissue sampling for the most common forms of cancer.”

Board Member Dr Charles Walther – Founder of BiBB